LONDON - AstraZeneca said Monday that late-stage trials showed that its COVID-19 vaccine with Oxford University was up to 90% effective in preventing disease.The results are based on interim analysis of trials in the U.K.
and Brazil of a vaccine developed by Oxford University and manufactured by AstraZeneca. No hospitalizations or severe cases of COVID-19 were reported in those receiving the vaccine, AstraZeneca said.READ MORE: First U.S.
coronavirus vaccinations could happen Dec. 12The trial looked at two different dosing regimens. A half dose of the vaccine followed by a full dose at least one month apart was 90% effective.